PE20060373A1 - Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 - Google Patents

Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2

Info

Publication number
PE20060373A1
PE20060373A1 PE2005000715A PE2005000715A PE20060373A1 PE 20060373 A1 PE20060373 A1 PE 20060373A1 PE 2005000715 A PE2005000715 A PE 2005000715A PE 2005000715 A PE2005000715 A PE 2005000715A PE 20060373 A1 PE20060373 A1 PE 20060373A1
Authority
PE
Peru
Prior art keywords
piperidinyl
carboxamide
inhibitors
indazol
kinase activity
Prior art date
Application number
PE2005000715A
Other languages
English (en)
Inventor
Jeffrey K Kerns
Christine Edwards
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060373A1 publication Critical patent/PE20060373A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Z ES ARILO O HETEROARILO SUSTITUIDO O NO CON HALO, ALQUILO C1-C6, CN, ENTRE OTROS; R1 ES H, HALO, WX; W ES UN ENLACE, ALQUILENO C1-C6; X ES ARILO, HETEROARILO, HETEROCICLOALQUILO, CICLOALQUILO C4-C7, ENTRE OTROS.SON COMPUESTOS PREFERIDOS: 4-[7-(AMINOCARBONIL)-5-FENIL-1H-INDAZOL-3-IL]-1-PIPERIDINCARBOXILATO DE 1,1-DIMETILETILO; HIDROCLORURO DE 5-FENIL-3-(4-PIPERIDINIL)-1H-INDAZOL-7-CARBOXAMIDA; 3-{1-[(1,2-DIMETIL-1H-IMIDAZOL-4-IL)SULFONIL]-4-PIPERIDINIL}-5FENIL-1H-INDAZOL-7-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE IKK2, UTILES EN EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS Y DE REPARACION TISULAR TALES COMO ARTRITIS REUMATOIDE, ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2005000715A 2004-06-24 2005-06-22 Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 PE20060373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58265504P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
PE20060373A1 true PE20060373A1 (es) 2006-04-29

Family

ID=35782386

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000715A PE20060373A1 (es) 2004-06-24 2005-06-22 Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2

Country Status (21)

Country Link
US (1) US8501780B2 (es)
EP (1) EP1758578B1 (es)
JP (1) JP5017105B2 (es)
KR (1) KR20070043940A (es)
CN (1) CN101005836A (es)
AR (1) AR050253A1 (es)
AT (1) ATE493396T1 (es)
AU (1) AU2005258332A1 (es)
BR (1) BRPI0512533A (es)
CA (1) CA2571712A1 (es)
DE (1) DE602005025632D1 (es)
ES (1) ES2358579T3 (es)
IL (1) IL179747A0 (es)
MA (1) MA28727B1 (es)
MX (1) MXPA06014481A (es)
NO (1) NO20070076L (es)
PE (1) PE20060373A1 (es)
RU (1) RU2007102576A (es)
TW (1) TW200616967A (es)
WO (1) WO2006002434A2 (es)
ZA (1) ZA200609759B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
PE20070173A1 (es) * 2005-06-30 2007-03-14 Smithkline Beecham Corp Compuestos de indol carboxamidas como inhibidores de ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2007062318A2 (en) * 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
BRPI0707718A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto
JP5019768B2 (ja) * 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0804591D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010120854A1 (en) * 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
JP2015214492A (ja) * 2012-09-07 2015-12-03 大日本住友製薬株式会社 ３−（４−ピペリジル）−インダゾール誘導体
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
KR102490953B1 (ko) 2016-09-23 2023-01-19 노파르티스 아게 힘줄 및/또는 인대 손상에 사용하기 위한 인다졸 화합물
JOP20210324A1 (ar) * 2019-06-27 2023-01-30 Biogen Ma Inc مشتقات من 2h-indazole واستخدامها في علاج مرض

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775761A (en) * 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US5256673A (en) * 1983-11-25 1993-10-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
DE3342632A1 (de) 1983-11-25 1985-06-05 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
EP0279263B1 (en) 1987-02-10 1993-08-04 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
JPH0262875A (ja) * 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
PH30133A (en) 1989-09-07 1997-01-21 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing lipoxygenase inhibiting compounds
US5254473A (en) * 1990-03-16 1993-10-19 Jp Laboratories Solid state device for monitoring integral values of time and temperature of storage of perishables
JP2963288B2 (ja) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
US5330986A (en) * 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1994021627A1 (en) 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
DE19500689A1 (de) 1995-01-12 1996-07-18 Merck Patent Gmbh Indolpiperidin-Derivate
BR9609353A (pt) 1995-06-07 1999-05-11 Sugen Inc Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP1077213A3 (en) 1996-06-14 2001-06-13 Eli Lilly And Company Inhibition of serotonin reuptake
EP0922042A1 (en) 1996-08-09 1999-06-16 Smithkline Beecham Corporation Novel piperazine containing compounds
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
PL338453A1 (en) 1997-08-06 2000-11-06 Lilly Co Eli 2-acylaminopropanoamines as antagonists of the tachykinin receptor
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
DE19756036A1 (de) 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
DE19807993A1 (de) 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
JP4342101B2 (ja) 1998-02-27 2009-10-14 キッセイ薬品工業株式会社 インドール誘導体および当該誘導体を含有する医薬品組成物
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
DE19928424A1 (de) 1999-06-23 2000-12-28 Aventis Pharma Gmbh Substituierte Benzimidazole
CZ302775B6 (cs) 1999-06-23 2011-11-02 Sanofi - Aventis Deutschland GmbH Substituovaný benzimidazol
JP2003506483A (ja) * 1999-08-13 2003-02-18 ベラ・ファーマシューティカルズ・インコーポレイテッド シクロベンザプリンおよびその組成物による全般性不安障害の処置
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
BR0015401A (pt) 1999-11-08 2002-07-02 Wyeth Corp [(indol-3-il)-cicloalquil]-3-azetidinas substituìdas para o tratamento de distúrbios do sistema nervoso central
US6245799B1 (en) * 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1209158A1 (en) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substituted beta-carbolines
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1134221A1 (en) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
CA2407370A1 (en) * 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
TWI306859B (en) 2000-04-28 2009-03-01 Acadia Pharm Inc Muscarinic agonists
EP1293206A4 (en) 2000-05-15 2005-09-21 Kissei Pharmaceutical LIQUID PREPARATION BASED ON WATER
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
EP1311502A1 (en) 2000-08-17 2003-05-21 Celltech R&D Limited Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders
US6868504B1 (en) * 2000-08-31 2005-03-15 Micron Technology, Inc. Interleaved delay line for phase locked and delay locked loops
RU2003106192A (ru) * 2000-09-06 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Способ лечения аллергий
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
CA2424303A1 (en) 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
WO2002030353A2 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
WO2002030423A1 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
CN1503673A (zh) 2000-10-26 2004-06-09 �㽭�пؼ����ɷ����޹�˾ 消炎药
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ATE368658T1 (de) 2000-12-22 2007-08-15 Wyeth Corp Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
EP1363993A4 (en) 2001-02-01 2008-11-12 Bristol Myers Squibb Co METHOD FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES USING I KAPPA B KINASE (IKK)
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
CA2447021C (en) 2001-05-24 2010-08-10 Leo Pharma A/S Pyridyl cyanoguanidine compounds
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
MXPA03011244A (es) * 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
US6638679B2 (en) 2001-07-12 2003-10-28 Kodak Polychrome Graphics, Llc Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20030127204A1 (en) 2001-09-06 2003-07-10 Varnell Daniel F. Amphoteric polymer resins that increase the rate of sizing development
US20030109550A1 (en) 2001-09-19 2003-06-12 Michael Clare Substituted indazole compounds for the treatment of inflammation
EP1427706B1 (en) 2001-09-19 2007-05-30 Pharmacia Corporation Substituted pyrazolo compounds for the treatment of inflammation
MXPA04002667A (es) 2001-09-19 2004-06-18 Pharmacia Corp Compuestos de pirazolilo sustituido para el tratamiento de la inflacion.
WO2003027075A2 (en) 2001-09-19 2003-04-03 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
CA2464924A1 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
DK1476136T3 (da) 2002-02-14 2006-10-09 Glaxo Group Ltd Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering
WO2003084959A1 (en) 2002-04-03 2003-10-16 Bristol-Myers Squibb Company Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
AR039280A1 (es) * 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
CA2485298C (en) 2002-05-09 2008-03-11 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
AU2003227522A1 (en) 2002-05-30 2003-12-19 Neurosearch A/S 3-substituted quinuclidines and their use
AU2003237330A1 (en) 2002-06-06 2003-12-22 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
WO2003104218A1 (en) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Nf-:b inhibitors
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
MXPA05002297A (es) 2002-08-29 2005-06-08 Boehringer Ingelheim Pharma Derivados-3(sulfoamidoetil)-indol para uso como compuestos mimeticos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas.
US6911445B2 (en) 2002-09-12 2005-06-28 Wyeth Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
AU2003298693B2 (en) 2002-11-22 2010-09-30 Smithkline Beecham Corporation Novel chemical compounds
AU2003286180B2 (en) * 2002-12-02 2009-11-12 F. Hoffmann-La Roche Ag Indazole derivatives as CRF antagonists
JP2006510676A (ja) * 2002-12-06 2006-03-30 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
WO2004075846A2 (en) 2003-02-25 2004-09-10 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7329764B2 (en) 2003-07-31 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Substitute benzothiophene compounds
WO2005035527A1 (en) 2003-10-14 2005-04-21 Pharmacia Corporation Substituted pyrazinone compounds for the treatment of inflammation
US20060004043A1 (en) * 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0400895D0 (en) 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
DE102004012069A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
AU2006321284B2 (en) 2005-04-13 2012-06-21 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
ES2372701T3 (es) * 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
US20080262040A1 (en) * 2005-10-25 2008-10-23 Smithkline Beecham Corporation Chemical Compounds
EP1940296A2 (en) * 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemical compounds
WO2007062318A2 (en) * 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
JP2009519968A (ja) * 2005-12-16 2009-05-21 スミスクライン・ビーチャム・コーポレイション 化学物質
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
PE20080925A1 (es) * 2006-09-22 2008-09-04 Glaxo Group Ltd DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
GB0804592D0 (en) 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors

Also Published As

Publication number Publication date
MXPA06014481A (es) 2007-03-01
EP1758578A4 (en) 2009-05-27
NO20070076L (no) 2007-02-26
MA28727B1 (fr) 2007-07-02
KR20070043940A (ko) 2007-04-26
CN101005836A (zh) 2007-07-25
ATE493396T1 (de) 2011-01-15
EP1758578A2 (en) 2007-03-07
BRPI0512533A (pt) 2008-03-25
JP5017105B2 (ja) 2012-09-05
AR050253A1 (es) 2006-10-11
US20070281933A1 (en) 2007-12-06
DE602005025632D1 (de) 2011-02-10
JP2008504296A (ja) 2008-02-14
RU2007102576A (ru) 2008-07-27
TW200616967A (en) 2006-06-01
CA2571712A1 (en) 2006-01-05
WO2006002434A2 (en) 2006-01-05
US8501780B2 (en) 2013-08-06
AU2005258332A1 (en) 2006-01-05
IL179747A0 (en) 2007-05-15
ZA200609759B (en) 2007-10-31
ES2358579T3 (es) 2011-05-11
WO2006002434A3 (en) 2006-06-15
EP1758578B1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
PE20060373A1 (es) Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) Derivados de indolcarboxamida como inhibidores de quinasa ikk2
NO20063928L (no) Substituerte kinolinforbindelser
PE20070217A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
PE20070646A1 (es) COMPUESTOS CON ESTRUCTURA DE CINAMIDA DE TIPO MORFOLINA COMO INHIBIDORES DE LA PRODUCCION DE ß-AMILOIDE
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
PE20040589A1 (es) Tiazolidinonas y su preparacion como medicamentos
WO2010018109A3 (en) Substituted aminotetralines
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
AR071314A1 (es) Antagonistas de receptor de cgrp
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
MX2009010270A (es) Indol carboxamidas como inhibidores de quinasas ikappa2.
PE20070619A1 (es) TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
PE20090595A1 (es) Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
WO2010018112A3 (en) Monoaryl aminotetralines
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
TR200103490T2 (tr) Antihistaminik ve antialerjik maddeler olarak indolilpiperidin türevleri
EA200800183A1 (ru) Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
FC Refusal